Table 2.
COVID-19 positive versus negative | ||
---|---|---|
Classifier validation (cross-validation) | ||
Positive (n) | Negative (n) | |
Assigned positive | 195 | 46 |
Assigned negative | 55 | 204 |
Sensitivity | Specificity | |
0.78* (0.74–0.81) | 0.82* (0.78–0.85) | |
LR+ | LR- | |
4.24* (3.24–5.55) | 0.27* (0.21–0.34) | |
Classifier independent testing | ||
Positive (n) | Negative (n) | |
Assigned positive | 59 | 7 |
Assigned negative | 15 | 29 |
Sensitivity | Specificity | |
0.80* (0.72–0.86) | 0.81* (0.73–0.87) | |
LR+ | LR- | |
4.10* (2.09–8.05) | 0.25* (0.16–0.41) | |
Human independent testing (Reader 1) | ||
Positive (n) | Negative (n) | |
Assigned positive | 47 | 8 |
Assigned negative | 27 | 28 |
Sensitivity | Specificity | |
0.64 (0.52–0.74) | 0.78 (0.61–0.90) | |
LR+ | LR- | |
2.86 (1.51–5.39) | 0.47 (0.33–0.66) | |
Human independent testing (Reader 2) | ||
Assigned positive | 47 | 5 |
Assigned negative | 27 | 31 |
Sensitivity | Specificity | |
0.64 (0.52–0.74) | 0.86 (0.71–0.95) | |
LR+ | LR- | |
4.57 (1.99–10.50) | 0.42 (0.31–0.59) |
Data are presented as value and 95% confidence interval. *p < 0.005. COVID-19 Coronavirus disease 2019, LR+ Positive likelihood ratio, LR- Negative likelihood ratio